Your email has been successfully added to our mailing list.

×
0 0 -0.0268456375838925 -0.0268456375838925 -0.0268456375838925 -0.00724832214765095 -0.026711409395973 -0.0402684563758388
Stock impact report

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain [Seeking Alpha]

Heron Therapeutics, Inc. (HRTX) 
Last heron therapeutics, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: herontherapeutics.gcs-web.com/investor-home
Company Research Source: Seeking Alpha
The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. The availability of a vial access needle form of Zynrelef might not come until late 2024, but offers an additional milestone for Zynrelef's expansion. Heron Therapeutics ( NASDAQ: HRTX ) has seen a positive start to 2024, with approval of the company's supplemental New Drug Application (sNDA) for Zynrelef allowing the drug to be used in more surgical procedures. I Recommended For You Recommended For You About HRTX Stock Related Stocks Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HRTX alerts
Opt-in for
HRTX alerts

from News Quantified
Opt-in for
HRTX alerts

from News Quantified